# Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

> **NCT06109467** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 36 (estimated)

## Conditions studied

- GastroEsophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Trastuzumab
- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil + leucovorin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06109467
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-12
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109467, "Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06109467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*